Olshan lawyers frequently represent companies, investment groups, and leading global research institutions in formation, financing, mergers & acquisitions and tech transfer transactions, as well as in litigation, restructuring, regulatory and general commercial counseling in the healthcare, life sciences and pharmaceutical space.
- Represent a leading academic medical and research center in numerous technology transfer transactions, including as to resulting equity investments.
- Represent a life science investment entity in numerous initial and follow on preferred equity investments, technology transfer transactions and other commercial arrangements, including with each of NYU Langone Medical Center and Massachusetts General Hospital.
- Represent PLx Pharma, Inc., a Nasdaq listed late-stage specialty pharmaceutical company, in connection with all legal matters other than patents.
- Represent Modern Meadow, an American biotechnology company that uses biofabrication to create sustainable materials, in joint venture, supply and license agreements, intellectual property work and general corporate advice.
- Represented Harvard Bioscience, Inc., a Nasdaq-listed global developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and preclinical testing for drug development, in public company reporting, compliance and transactional matters.
- Represented Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction, in its $21 million initial public offering and listing on The Nasdaq Capital Market under the symbol ANEB.
- Represented Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, in a $14.4 million initial public offering of 2,875,000 shares of its common stock and Nasdaq listing under the symbol ALZN.
- Represented DASH Pharmaceutical, a specialty pharmaceutical company that develops and distributes high-quality generic pharmaceutical products, in the sale of 50% of its membership interests to CBC Capital USA Inc. and subsequently in the sale of all of its membership interests to a subsidiary of NATCO Pharma Limited, a multinational pharmaceutical company. In addition, represented in connection with master collaboration and supply agreements and general advertising matters including agreements and FDA compliance.
- Represented IMAC Holdings, Inc., a Nasdaq-listed provider of innovative medical advancements and care specializing in regenerative and rehabilitation orthopedic treatments, in the underwritten initial public offering of IMAC’s shares of common stock and warrants to purchase common stock and in a $19.55 million underwritten follow-on public offering of its shares of common stock.
- Represented The Benchmark Company, LLC, acting as sole placement agent, in a brokered private placement of 16,357,703 units of Assure Holdings Corp., a Nasdaq-listed Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries, for gross proceeds of over $10 million.
- Represented Aegis Capital Corp. as sole bookrunner and representative of the several underwriters in NanoViricides, Inc.’s (NYSE American: NNVC) $8.65 million follow-on equity public offering of 2,875,000 shares of common stock, including the underwriters’ full exercise of their 375,000 over-allotment option. NanoViricides is a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform.
- Represented Pharmacyclics, Inc., a Nasdaq listed clinical-stage biopharmaceutical company, in connection with a $57.4 million registered direct offering of its common stock.
- Represented CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of cardiorenal disease, in connection with its initial public offering and related listing on NYSE American.
- Represented Biotechnology Value Fund, L.P., a fund that invests in biotechnology companies, in activist matters and SEC filings.
- Represented Ramius LLC in a tender offer and acquisition of Cypress Bioscience, Inc. (Nasdaq: CYPB) in a transaction valued at $255 million.
- Represented Xstelos Holdings, Inc. (formerly Footstar, Inc.) in the acquisition of 80.5% of CPEX Pharmaceuticals, Inc. (Nasdaq:CPEX), a publicly-traded specialty pharmaceutical company, in a transaction valued at $76 million.
- Represented Aceto Corporation in marketing, sales and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products and specialty chemicals.
- Represented Acorda Therapeutics Inc., a biotechnology company focused on developing therapies that restore function and improve the lives of people with MS, spinal cord injury and other neurological conditions, in various employment matters.
- Represented Scerene Healthcare in connection with its formation, financing and dissolution.
- Represented Pfizer Inc., a premier -based biopharmaceutical company, in labor and employment work involving the closing of facilities, transfer of employees and union election work.
- Represented Caymus Equity Partners in partnering in the acquisition of, and securing senior and mezzanine financing for, a controlling interest in Excel Orthopedic Rehabilitation, a premier provider of sports and orthopedic physical therapy and rehabilitation services.
- Represented Dr. Knoll Products Inc. d/b/a Biowell Natural Health, a manufacturer and marketer of pharmaceutical-grade natural formulas, in telemarketing work.
- Represented Flora, Inc., a manufacturer and supplier of premium herbal products, in advertising matters.
- Represented Pernix Therapeutics Holdings Inc., a manufacturer and marketer of branded, generic and OTC pharmaceutical products, in advertising matters.
- Represented Leading Pharma, LLC, a privately owned generic pharmaceutical company that purchases, licenses, develops, manufactures and distributes high-quality, safe and effective products to drugstore chains, distributors, wholesalers, mass merchandisers, government agencies and managed care accounts in the U.S., in general advertising matters including agreements and FDA compliance.
- Represented Rising Pharmaceuticals, Inc., a developer, manufacturer, marketer, and distributor of prescription and over-the-counter pharmaceutical products, for FDA compliance and litigation involving Lanham Act.
- Represented CorMedix, Inc., a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, in general corporate matters from early private financing rounds through its IPO and public company reporting.
- Represented IASO Pharma Inc., a biopharmaceutical company focused on acquiring, developing and commercializing drugs for the treatment and prevention of infectious diseases and other serious illnesses, in Private Placement and Rights Offering.
- Represented Asphelia Pharmaceuticals, Inc., a Biotechnology company founded to develop and commercialize therapeutic products for the treatment of autoimmune disorders in Private Placement.
- Represented a public company in $538 million acquisition of a diversified manufacturer in the medical device space, through a combination of cash, stock and debt assumption.
- Represented a public company in the acquisition of a diagnostic imaging equipment reseller and service provider.
- Represented investors and board members in numerous publicly traded health care and life science companies with regard to governance and the election of directors.
- Represented the dealer manager in a rights offering by a public traded cancer diagnostic company.
- Serve as regular outside securities counsel for the market leading provider of housekeeping services to long-term care facilities, including in connection with the $30 million acquisition of substantially all of the assets of a health care facility service provider, through a combination of cash, stock, and debt assumption.
